Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer
Molecular Oncology · 2026
DOI: 10.1002/1878-0261.70305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2026. Verfasst von Ashlyn Conant und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biochemistry, Department of Basic Sciences, Loma Linda University, California, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Drug Resistance, Neoplasm, Interferon-beta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Loma Linda University, National Cancer Institute.
Abstract (Originalsprache)
Type 1 interferon (IFN‐1) production and signaling are frequently activated in response to DNA damage and have been associated with the development of therapy resistance in cancer. However, the cell‐autonomous role of IFN‐1 in driving resistance in high‐grade serous ovarian cancer (HGSOC) remains unclear. Specifically, whether IFN‐1 functions in HGSOC as solely a response to genotoxic stress due to genotoxic therapy as frontline treatment, or can independently act in driving resistance phenotypes, has not been studied. Utilizing a patient‐derived model of cisplatin‐sensitive (SE) and ‐resistant (CR) HGSOC, we demonstrate that chronic cisplatin exposure is associated with enrichment of IFN‐1 signaling and an interferon‐related DNA damage resistance signature. Acute cisplatin treatment elicited dynamic IFN‐1 signaling in both SE and CR cells, indicating a conserved stress response. However, chronic, low‐level exposure to exogenous IFNβ, without a DNA‐damaging agent, phenocopied several features of chronic cisplatin‐driven resistance, including reduced therapeutic sensitivity and decreased proliferation. Together, these findings identify IFNβ as a driver of resistance‐associated phenotypes and highlight cell‐autonomous IFN‐1 signaling as a potential biomarker for resistance and therapeutic target in platinum‐resistant disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Biochemistry, Department of Basic Sciences, Loma Linda University, California, USA.
- Department of Biochemistry, Whitworth University, Spokane, Washington, USA.
- Division of Cancer Sciences, Department of Basic Sciences, Loma Linda University, California, USA.
- Department of Biology, University of Redlands, California, USA.
- Department of Gynecology and Obstetrics, Loma Linda University, California, USA.
- Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Loma Linda University, California, USA.
ORCID-Profile: V S S Abhinav Ayyadevara, Juli J Unternaehrer
Förderung
- NCI NIH HHS
- Loma Linda University
- National Cancer Institute
Zitieren
APA
Conant, A., Suzuki, T., McGivney, K., Ayyadevara, V. S. S. A., Asariah, S., Deng, J., Nyein, E., Coats, J., Yu, G., Ioffe, Y. J., Hurtz, C., & Unternaehrer, J. J. (2026). Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.70305
Vancouver
Conant A, Suzuki T, McGivney K, Ayyadevara VSSA, Asariah S, Deng J, et al. Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer. Molecular Oncology. 2026. doi:10.1002/1878-0261.70305
BibTeX
@article{Conant2026,
author = {Conant, Ashlyn and Suzuki, Tise and McGivney, Kiera and Ayyadevara, V S S Abhinav and Asariah, Sharon and Deng, Jay and Nyein, Ethan and Coats, Jacqueline and Yu, Gary and Ioffe, Yevgeniya J and Hurtz, Christian and Unternaehrer, Juli J},
title = {Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer},
journal = {Molecular Oncology},
year = {2026},
doi = {10.1002/1878-0261.70305}
}
EUVIMED